Loading
A phase 3 trial of Teclistamab, Daratumumab, Lenalidomide in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT05552222 by Janssen Research & Development, LLC, with 1590 participants planned, started 2022-10-25 and due to reach its primary completion in 2031-04-30. Interventions recorded: Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Talquetamab, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Talquetamab, Teclistamab, Daratumumab, Lenalidomide.
Shares Talquetamab, Teclistamab, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Lenalidomide, Dexamethasone.
Shares Talquetamab, Teclistamab, Johnson & Johnson, T-cell engagers (bispecific).